The significance of this co-expression is notable, as treatments targeting CD22, such as inotuzumab ozogamicin, have been highly effective, achieving complete remissions in a large proportion of patients with relapsed or refractory B-ALL [37]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.